China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment and dosing in its Phase II study for STC3141, a sepsis therapy developed by Grand Medical Pty Ltd, the company’s innovative drug R&D center in Australia. The preliminary results of the study are anticipated by March 2025.
Phase II Study Design and Patient Recruitment
The Phase II study is a multi-center, randomized, double-blinded, placebo-controlled dosage exploration study aimed at evaluating the efficacy, safety, and pharmacokinetics of STC3141 in sepsis patients. The study successfully recruited 180 patients who received standard treatment and care, with a five-day intravenous administration of STC3141 followed by a 28-day follow-up period.
STC3141: A Novel Sepsis Therapy with a Unique Mechanism
STC3141 is a groundbreaking drug with a novel mechanism of action that addresses the organ damage caused by excessive immune responses in the body. It works by neutralizing extracellular histones and neutrophil traps, which are key mediators in the pathogenesis of sepsis. This innovative approach is being tested across multiple indications, including sepsis and acute respiratory distress syndrome (ARDS).-Fineline Info & Tech
